Why the study?
Does dual antiplatelet therapy compared to triple antithrombotic therapy prevent thromboembolic events and reduce bleeding in patients post-PCI for anterior STEMI with LVEF ≤35%?
Population
124 patients who received percutaneous coronary intervention for anterior ST elevation myocardial infarction…
Comparison
Dual antiplatelet therapy (DAPT) vs Triple antithrombotic therapy consisting of…
Design
Cohort
Key result
Dual antiplatelet therapy was associated with similar rates of thromboembolic events (5% vs 6.8%, P=0.70) and bleeding (2.5% vs 9.1%, P=0.18) compared to triple therapy after PCI for anterior STEMI.
Authors
Loading...
May favor DAPT to limit bleeding without excess thromboembolism in anterior STEMI with low EF; leaves open randomized confirmation.
Cohort (n=124)
Does dual antiplatelet therapy compared to triple antithrombotic therapy prevent thromboembolic events and reduce bleeding in patients post-PCI for anterior STEMI with LVEF ≤35%?
Absolute Event Rate: 5% vs 6.8%
p-value: p=0.70
In patients with anterior STEMI and LVEF ≤35% undergoing PCI, DAPT showed similar rates of thromboembolic events and numerically lower bleeding compared to triple therapy, challenging the routine use of warfarin in this population.
Oyetayo et al. (2015) conducted a cohort in Anterior STEMI with depressed LVEF (n=124). Dual antiplatelet therapy (DAPT) vs. Triple antithrombotic therapy (TT) was evaluated on Thromboembolic events (p=0.70). Dual antiplatelet therapy was associated with similar rates of thromboembolic events (5% vs 6.8%, P=0.70) and bleeding (2.5% vs 9.1%, P=0.18) compared to triple therapy after PCI for anterior STEMI.